A plaintiff, Monique T., has filed a blood thinner Xarelto lawsuit against the manufacturers of the drug after she suffered serious side effects. Other plaintiffs have come forward with similar blood thinner Xarelto lawsuits after patient complaints and research studies have shown a serious risk of internal bleeding while taking the drug.

Blood Thinner Xarelto Lawsuit Blames Manufacturers for Injuries 

Monique T. argues that she was never warned about the risks or told how to monitor for severe internal bleeding. She says she was initially prescribed the medication in June 2016. Unfortunately, according to her blood thinner Xarelto lawsuit, she developed excessive vaginal bleeding and had to seek treatment at the hospital.

The statements in her Xarelto lawsuit explain that she was admitted to Laurel Regional Hospital in Maryland with a hemoglobin level of 6.2, requiring a transfusion of blood. She had to stay in the hospital for several days in order to recover from this situation.

Her blood thinner Xarelto lawsuit details that she was never warned about the risks of serious internal bleeding or given an explanation about what to do if it happened when she got her prescription. Monique says the manufacturer, Janssen Pharmaceuticals, is responsible for the injuries she sustained and the associated expenses tied to the excessive vaginal bleeding.

After returning home from the hospital, she discontinued her use of Xarelto immediately based on medical recommendations from her doctors.

Xarelto and Blood Thinner Use

As explained in the blood thinner Xarelto lawsuit, this popular oral anticoagulant is marketed as a safe and better blood thinner when compared with warfarin.

The primary reason for a doctor to prescribe Xarelto is to cut down on the risk of systemic embolism and stroke for those patients with non-valvular atrial fibrillation. The drug may also be used to reduce deep vein thrombosis for patients or to manage DVT and pulmonary embolism.

Many patients who ultimately filed a blood thinner Xarelto lawsuit say they were never warned by the drug manufacturer about the risks. Many patients have reported serious side effects associated with internal bleeding, and some of these lawsuits allege that the patients suffered fatal injuries because of the drug’s defects.

As with many other similar lawsuits against the makers of Xarelto, this lawsuit alleges that the studies used to support the FDA approval of Xarelto and to underpin the drug’s safety and efficacy were flawed in nature and failed to consider the internal bleeding risks for patients.

Internal bleeding is a serious medical complication that, if not caught early, could lead to fatal injuries. Xarelto’s manufacturers are also accused of failing to put a safe antidote to the drug on the market in an effective and timely fashion. Allegedly this fact, in addition to failing to notify the medical community and patients about the high risk of bleeding, put people at risk of critical injuries or death. Those patients may be eligible to pursue a defective drug lawsuit.

The Blood Thinner Xarelto Lawsuit is Case No. 2:18-cv-01267-EEF-MBN filed in the U.S. District Court for the Eastern District of Louisiana.